Lunit Oncology

Lunit Oncology specializes in the development of cutting-edge, AI-powered medical image analysis software. With a dedicated team of over 300 professionals, including more than 70 researchers, 10 medical doctors, and a group of oncologists and pathologists, Lunit Oncology is at the forefront of innovation in oncology solutions. Their work is consistently featured in prestigious journals such as the Journal of Clinical Oncology and Clinical Cancer Research.

Lunit Oncology's AI-powered multimodal analysis is revolutionizing oncology research and clinical practice. Their Lunit SCOPE IO facilitates comprehensive tumor microenvironment assessment through quantitative immune phenotyping, enabling more rapid and precise biomarker identification. Lunit SCOPE uIHC offers advanced quantification and feature scoring for IHC analysis across various tissue types and IHC markers. The innovative Lunit SCOPE GP predicts genotype modalities, providing insights into specific gene expression and mutations directly from H&E images.

Lunit Oncology's technology optimizes clinical trial processes and powers PD-L1 scoring for Guardant Health's Galaxy PD-L1 tissue testing. Through global collaborations, Lunit Oncology continues to advance oncology therapeutic biomarkers, driven by a steadfast commitment to innovation and excellence. We invite the manager of Lunit Oncology to create a customized and exclusive company showcase and product listing on our platform.